Alzheon, Inc. today announced that it has successfully dosed the first cohort of healthy volunteers in a Phase 1 clinical trial evaluating ALZ-507, an investigational oral small molecule designed for the treatment of Alzheimer’s disease and related neurodegenerative conditions.

The Phase 1 study is a randomized, double-blind, placebo-controlled single and multiple ascending dose trial intended to evaluate the safety, tolerability, and pharmacokinetics of ALZ-507 in healthy adult participants. The trial marks a key milestone in the clinical development of the compound, which represents a next-generation approach to targeting amyloid pathology.

ALZ-507 is designed to inhibit the formation of neurotoxic soluble amyloid oligomers while also incorporating an APOE4-targeted corrective mechanism, a strategy intended to address one of the most significant genetic risk factors associated with Alzheimer’s disease progression. The investigational therapy is being developed as a once-daily oral capsule, with the goal of improving patient convenience and gastrointestinal tolerability compared with earlier-generation approaches.

According to the company, the ALZ-507 Investigational New Drug (IND) program demonstrated a favorable nonclinical safety and pharmacokinetic profile, supporting advancement into human clinical testing and enabling once-daily oral dosing.

Phase 1 Objectives and Clinical Design

The ongoing Phase 1 study will assess escalating dose levels in sequential cohorts of healthy volunteers. Primary endpoints include safety and tolerability, while secondary endpoints focus on pharmacokinetic parameters such as absorption, distribution, metabolism, and elimination.

Data generated from the trial are expected to inform optimal dose selection and formulation strategy for subsequent Phase 2 studies in patient populations, including individuals with Alzheimer’s disease, Down syndrome–associated Alzheimer’s disease, and cerebral amyloid angiopathy.

Pipeline Expansion and Precision Medicine Strategy

ALZ-507 expands Alzheon’s precision medicine pipeline, which also includes valiltramiprosate (ALZ-801), an oral investigational therapy currently in Phase 3 development for Alzheimer’s disease. The company has previously reported that ALZ-801 demonstrated clinical efficacy in patients with mild cognitive impairment and maintained a favorable safety profile, including no observed increase in brain vasogenic edema, a concern associated with some amyloid-targeting therapies.

With ALZ-507, Alzheon aims to build on this approach by advancing a differentiated, next-generation candidate designed for improved tolerability and disease-modifying potential through dual targeting of amyloid oligomer formation and APOE4-related mechanisms.

Looking Ahead

If successful, Phase 1 results will guide dose optimization and support the design of later-stage clinical trials. The company intends for ALZ-507 to further strengthen its oral, precision-medicine-focused strategy for addressing Alzheimer’s disease and related neurodegenerative disorders.